China Universal Asset Management Co. Ltd. Raises Stock Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

China Universal Asset Management Co. Ltd. boosted its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 60.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,024 shares of the company’s stock after acquiring an additional 2,646 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in iTeos Therapeutics were worth $72,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of iTeos Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock valued at $20,468,000 after purchasing an additional 9,660 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in iTeos Therapeutics in the first quarter worth about $3,337,000. Public Employees Retirement System of Ohio grew its stake in shares of iTeos Therapeutics by 4.9% during the first quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock worth $532,000 after acquiring an additional 1,817 shares during the last quarter. Kennedy Capital Management LLC purchased a new stake in shares of iTeos Therapeutics during the first quarter worth about $1,988,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of iTeos Therapeutics by 4.7% during the second quarter. Bank of New York Mellon Corp now owns 121,250 shares of the company’s stock valued at $1,799,000 after acquiring an additional 5,409 shares in the last quarter. 97.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a research report on Monday, September 16th. Wells Fargo & Company initiated coverage on shares of iTeos Therapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price objective on the stock. Wedbush restated an “outperform” rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research note on Thursday, August 8th. Finally, JPMorgan Chase & Co. dropped their price target on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th.

iTeos Therapeutics Price Performance

NASDAQ:ITOS opened at $8.45 on Friday. The company’s fifty day moving average price is $11.97 and its 200-day moving average price is $14.11. iTeos Therapeutics, Inc. has a 1-year low of $8.41 and a 1-year high of $18.75. The firm has a market capitalization of $308.61 million, a P/E ratio of -2.24 and a beta of 1.36.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.86. The company had revenue of $35.00 million for the quarter, compared to analyst estimates of $4.20 million. Equities analysts anticipate that iTeos Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.